These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 3958753)

  • 1. Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.
    Kempf RA; Grunberg SM; Daniels JR; Skinner DG; Venturi CL; Spiegel R; Neri R; Greiner JM; Rudnick S; Mitchell MS
    J Biol Response Mod; 1986 Feb; 5(1):27-35. PubMed ID: 3958753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
    Rinehart J; Malspeis L; Young D; Neidhart J
    Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma.
    Vugrin D; Hood L; Taylor W; Laszlo J
    Cancer Treat Rep; 1985; 69(7-8):817-20. PubMed ID: 4016792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.
    Trump DL; Elson PJ; Borden EC; Harris JE; Tuttle RL; Whisnant JK; Oken MM; Carignan JR; Ruckdeschel JC; Davis TE
    Cancer Treat Rep; 1987 Feb; 71(2):165-9. PubMed ID: 3802113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
    Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
    Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
    Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
    Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
    Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
    Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
    Figlin RA; deKernion JB; Maldazys J; Sarna G
    Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
    Kuzmits R; Scheithauer W; Ludwig H; Flener R
    Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of renal cell carcinoma. 3. Interferon therapy].
    Kobayashi M; Imai K; Kiren H; Nakai K; Saruki K; Umeyama T; Ito Y; Yamanaka H; Makino T; Machida M
    Hinyokika Kiyo; 1987 Apr; 33(4):508-14. PubMed ID: 3618421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.
    Vugrin D; Hood L; Laszlo J
    J Biol Response Mod; 1986 Aug; 5(4):309-12. PubMed ID: 3734846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
    Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of advanced renal cell carcinoma with subcutaneous administration of interleukin 2 and interferon-alpha].
    Hofmockel G; Theiss M; Bussen D; Wirth MP; Frohmüller HG
    Urologe A; 1994 Sep; 33(5):434-9. PubMed ID: 7974933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The treatment of renal cell carcinoma with recombinant human leukocyte interferon].
    Kawamura J; Yamauchi T; Hashimura T; Yoshida O; Kohnami T; Tomoyoshi T; Ogura K; Fukuyama T; Nakagawa K
    Hinyokika Kiyo; 1985 Mar; 31(3):377-86. PubMed ID: 4025077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.